Update Series Volume 36 (2017)
For the most timely topics and latest surgical techniques in urology, you won't want to miss the 2017 AUA Update Series—AUA's most popular self-study CME product.
- Concise, practical lessons on timely topics
- State-of-the-art surgical techniques
- Authors are among the best in their specialties
Earn up to 40 AMA PRA Category 1 Credits™
Now in its 36th installment, this invaluable resource continues the tradition of providing up-to-date information that helps you fulfill Part 2 of the Maintenance of Certification requirements recognized by the American Board of Urology. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology.
Benefit from leading urologists’ recommendations in 40 new lessons, which are delivered to you five lessons a month for eight months. Take advantage of a convenient, easy-to-access educational product that fits your individual learning style.
Subscribers can obtain CME credit instantly! Simply complete the content-related, online posttests to receive immediate CME credit.
The AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed in consultation with and edited by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available.
Hot Topics for 2017:
- Post-Finasteride Syndrome: What Is the Evidence and Why Is There a Controversy
- Circumcision: Who, Why and When?
- Genital Gender Affirming Surgery for Transgender Patients
- Contemporary Prostate Cancer Screening: Who to Screen and When to Biopsy
- Testosterone Therapy – Indications and Treatment
- Testis Biopsy and Surgical Sperm Retrieval
- Robotics in Female Pelvic Medicine – Indications and Who is not Appropriate
- Antibiotic Prophylaxis in Children: Current Controversies
Update Series is Available in Two Formats for 2017
Online Only: Optimized for easy viewing on your computer or mobile device. Lessons are accessible and printable anytime.
Bundle (Print and Online): Enjoy online access plus the print edition, featuring bookshelf-quality binding.
The American Urological Association designates this enduring material for a maximum of
40 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- Board candidates
After completing all 40 lessons, participants, will be able to apply their knowledge and competencies on the urologic topics covered in each article. Each of the 40 lessons has a specific objective specific to the related article.
Individual authors’ disclosures are located with their articles in each issue of The Update Series.
Victor Nitti, MD: Astellas: Health Publishing, Scientific Study or Trial; Allergan: Health Publishing, Scientific Study or Trial; Serenity Pharmeuticals: Investment Interest; Cook Myosite: Scientific Study or Trial
Brant Inman, MD, MS: Dendreon: Scientific Study or Trial; Abbott Laboratories: Scientific Study or Trial; Genentech, Inc.: Scientific Study or Trial; Combat Medical: Consultant or Advisor; FKD Therapies: Scientific Study or Trial; AstraZeneca: Consultant or Advisor; Taris Biomedical: Consultant or Advisor
Update Series Advisory Group
|Arthur Louis Burnett II MD||Endo Pharmaceuticals||Scientific Study or Trial||Yes|
|PFIZER||Scientific Study or Trial||Yes|
|National Institutes of Health||Scientific Study or Trial||Yes|
|Auxilium Inc||Scientific Study or Trial||Yes|
|American Medical Systems||Scientific Study or Trial||Yes|
|Coloplast||Scientific Study or Trial||Yes|
|Reflexonic LLC||Scientific Study or Trial||Yes|
|VIVUS||Health Publishing, Scientific Study or Trial||Yes|
|Acorda Therapeutics||Scientific Study or Trial||Yes|
|New England Research institute||Other||Yes|
|The Center for Intimacy after Cancer Therapy, Inc||Leadership Position||No|
|Journal of Sexual Medicine||Health Publishing||Yes|
|Andrology (journal)||Health Publishing||Yes|
|International Urology and Nephrology (journal)||Health Publishing||No|
|Genomic Health Inc||Consultant or Advisor||No|
|Practical Reviews in Urology||Health Publishing||Yes|
|European Urology||Health Publishing||No|
|Medispec||Scientific Study or Trial||No|
|Astellas||Consultant or Advisor, Scientific Study or Trial||Yes|
|Urology Times Editorial Council||Health Publishing||Yes|
|Lilly LLC||Consultant or Advisor, Scientific Study or Trial||Yes|
|Peter Robert Carroll, MD, MPH||NIH||Scientific Study or Trial||Yes|
|Department of Defense||Scientific Study or Trial||Yes|
|Myriad Genetics||Scientific Study or Trial||No|
|AUA Update||Leadership Position||Yes|
|Genomic Health||Scientific Study or Trial||No|
|Rodney Davis MD||Corrections Corp of America||Consultant or Advisor, Investment Interest||Yes|
|Shelby Englert||Nothing to disclose|
|E. Ann Gormley MD||SUFU Foundation||Leadership Position||No|
|Kevin Thomas McVary ,MD, FACS||Astellas||Scientific Study or Trial||Yes|
|Lilly/ICOS||Consultant or Advisor, Scientific Study or Trial, Other||Yes|
|NIDDK||Scientific Study or Trial||Yes|
|AMS||Consultant or Advisor, Scientific Study or Trial||Yes|
|Sophris||Scientific Study or Trial||Yes|
|David Christopher Miller ,MD||Blue Cross Blue Shield of Michigan||Other||Yes|
|Curtis Nickel, MD||Farr Laboratories||Consultant or Advisor||Yes|
|Tribute||Consultant or Advisor||Yes|
|Aquinox||Scientific Study or Trial||No|
|GSK||Scientific Study or Trial||No|
|PureTech Health||Consultant or Advisor||Yes|
|NIH||Scientific Study or Trial||Yes|
|Canadian Institute of Health Research||Scientific Study or Trial||Yes|
|Canadian Urological Association Pres-elect||Leadership Position||No|
|Craig Stuart Niederberger ,MD||AMERICAN SOCIETY FOR REPRODUCTIVE MEDICINE||Leadership Position, Meeting Participant or Lecturer||Yes|
|NexHand||Leadership Position, Investment Interest, Owner, Product Development||No|
|Ferring Pharmaceuticals||Scientific Study or Trial||Yes|
|Victor William Nitti MD||Astellas||Health Publishing, Scientific Study or Trial||No|
|Allergan||Health Publishing, Scientific Study or Trial||No|
|Serenity Pharmeuticals||Investment Interest||Yes|
|Cook Myosite||Scientific Study or Trial||No|
|Mrs.. Deborah F. Polly||Nothing to disclose|
|Eila Curlee Skinner, MD||Nothing to disclose|
|Stacy T. Tanaka MD||Nothing to disclose|
|J. Christian Winters MD||Astellas, Inc||Consultant or Advisor||Yes|
|Pfizer||Consultant or Advisor||Yes|
|Allergan||Consultant or Advisor||Yes|
|American Board of Urology||Leadership Position||No|
|Society of Urodynamics, Female Pelvic Medicine and Urogential Reconstruction||Leadership Position||No|
|Solace||Scientific Study or Trial||Yes|
|StimGuard||Consultant or Advisor||Yes|
|J. Stuart Wolf Jr. MD,FACS||Urology Times||Health Publishing||Yes|
|University of Michigan Dept of Urology||Leadership Position||Yes|
|University of Texas Department of Surgery & Peri-operative Care||Leadership Position||Yes|
This self-study continuing medical education activity is designed to provide urologists, Board candidates and/or residents affordable and convenient access to the most recent developments and techniques in urology.
Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation: The American Urological Association designates this enduring material for a maximum of 40.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME enduring material activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) participating in an educational activity provided by the AUA are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
Resolution of Identified Conflict of Interest: All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:
- Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor and/or Education Content Review Committee or its subgroup.
- Limit content to evidence with no recommendations
- Introduction of a debate format with an unbiased moderator (point-counterpoint)
- Inclusion of moderated panel discussion
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
- Divestiture of the relationship by faculty
Off-label or Unapproved Use of Drugs or Devices: It is the policy of the AUA to require the disclosure of all references to off-label or unapproved uses of drugs or devices prior to the presentation of educational content. The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.
Reproduction Permission: Reproduction of written materials developed for this AUA activity is prohibited without the written permission from individual authors and the American Urological Association.
Peer Review: Peer review is the principle mechanism by which the quality of the AUA Update Series content is judged by the AUA Update Series Advisory Board.
Released date: Release month, 2017
Expiration date: Release month, 2020
AUAER Privacy and Confidentiality Policy
Email the AUA Office of Education with any questions at firstname.lastname@example.org
- 40.00 AMA PRA Category 1 Credit™
- 40.00 Non-Physician Participation